VBI Vaccines (NASDAQ:VBIV) Stock Price Passes Below Two Hundred Day Moving Average of $0.62

VBI Vaccines Inc. (NASDAQ:VBIV) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.62 and traded as low as $0.61. VBI Vaccines shares last traded at $0.66, with a volume of 601,236 shares trading hands.

Analyst Ratings Changes

Separately, StockNews.com began coverage on shares of VBI Vaccines in a research note on Saturday. They set a “sell” rating on the stock.

VBI Vaccines Price Performance

The company has a fifty day simple moving average of $0.61 and a 200-day simple moving average of $0.61.

VBI Vaccines (NASDAQ:VBIV) last posted its quarterly earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.02). The company had revenue of $1.21 million during the quarter, compared to the consensus estimate of $2.85 million. VBI Vaccines had a negative net margin of 881.79% and a negative return on equity of 525.42%. On average, equities research analysts forecast that VBI Vaccines Inc. will post -1.23 EPS for the current fiscal year.

About VBI Vaccines

VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.